Computational design of targeted inhibitors of Polo-like Kinase 1 (PlK1)

Bioinformatics and Biology Insights

Volumn 6, Issue , 2012, Pages 23-31

  Jani, Krupa S ^a   Dalafave, D S ^a  

^a The College of New Jersey   (United States)

Author keywords

Computational drug design; Plk1 kinase inhibitors

Indexed keywords

LIGAND; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; PROTEIN KINASE LYN;

ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG ACTIVITY; HYDROGEN BOND; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN TARGETING;

EID: 84857814681     PISSN: None     EISSN: 11779322     Source Type: Journal    
DOI: 10.4137/BBI.S8971     Document Type: Article

References (60)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912-34.
2. Kothe M, Kohls D, Low S, et al. Structure of the catalytic domain of human Polo-Like Kinase 1. Biochemistry. 2007;46(20):5960-71.
3. Lowery DM, Lim D, Yaffe MB. Structure and function of polo-like kinases. Oncogene. 2005;24:248-59.
4. van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle. 2006;5:853-64.
5. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5:429-40.
6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28-39.
7. Hanks SK. Genomic analysis of the eukaryotic protein kinase super family: a perspective. Genome Biol. 2003;4(5):111.
8. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase super family: kinase (catalytic) domain structure and classification. FASEB J. 1995;9(8):576-96.
9. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2:358-64.
10. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol. 2002;9:268-72.
11. Grunwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie. 2007;30:519-24.
12. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of suni-tinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008; 99:448-54.
13. Elia AEH, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science. 2003;299:1228-31.
14. Liao C, Park J-E, Bang JK, Nicklaus MC, Lee KS. Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Med Chem Lett. 2010;1(3):110-4.
15. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci. 1994;107(6):1509-17.
16. Lindon C, Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol. 2004;164:233-41.
17. Lee KS, Grenfell TZ, Yarm FR, Erikson RL. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc Natl Acad Sci. U S A. 1998;95:9301-6.
18. Jang YJ, Ma S, Terada Y, Erikson RL. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. J Biol Chem. 2002;277:44115-20.
19. van de Weerdt BC, van Vugt MA, Lindon C, et al. Uncoupling anaphasepromoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Mol Cell Biol. 2005;25:2031-44.
20. van de Weerdt BC, Littler DR, Klompmaker R, et al. Polo-box domains confer target specificity to the Polo-like kinase family. Biochim Biophys Acta. 2008;1783(6):1015-22.
21. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321-30.
22. Petronczki M, Lenart P, Peters JM. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell. 2008;14(5):646-59.
23. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is over expressed in primary colorectal cancers. Cancer Sci. 2003;94:148-52.
24. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002;9:354-8.
25. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Acta Crystallogr D Biol Crystallogr. 2005;65:2698-704.
26. Elez R, Piiper A, Kronenberger B, et al. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene. 2003;22:69-80.
27. Lansing TJ, McConnell RT, Duckett DR, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther. 2007;6:450-9.
28. Santamaria A, Neef R, Eberspacher U, et al. Use of the novel Plk1 inhibitor ZK-Thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell. 2007;18:4024-36.
29. McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem. 2005;5:181-97.
30. Stevenson CS, Capper EA, Roshak AK, et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther. 2002;303:858-66.
31. Liu Y, Shreder KR, Gai W, Corral S, Ferris DK, Rosenblum JS. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian pololike kinase. Chem Biol. 2005;12:99-107.
32. Steegmaier M, Hoffmann M, Baum A, et al. Curr Biol. 2007;17:316-22.
33. Gumireddy K, Reddy MV, Cosenza SC, et al. Cancer Cell. 2005;7:275-86.
34. Davis-Ward R, Mook RAJ, Neeb MJ, Salovich JM. Preparation of pyrimidine derivatives as Polo-like kinases inhibitors for treatment of cancers. PCT Int Pat Appl Publ WO. 2004;2004074244.
35. Fancelli D, Berta D, Bindi S, et al. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005;48:3080-4.
36. Daub H. Characterisation of kinaseselective inhibitors by chemical proteomics. Biochim Biophys Acta. 2005;1754:183-90.
37. Daub H, Sprecht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004;3:1001-10.
38. Garcia-Alvarez B, de Carcer G, Ibanez S, Bragado-Nilsson E, Montoya G. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. Proc Natl Acad Sci U S A. 2007; 104(9):3107-12.
39. Yun SM, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol. 2009;16:876-82.
40. Hanisch A, Wehner A, Nigg EA, Sillje HH. Different Plk1 Functions Show Distinct Dependencies on Polo-Box Domain-mediated Targeting. Mol Biol Cell. 2006;17:448-59.
41. Elia AE, Rellos P, Haire LF, et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell. 2003;115(1):83-95.
42. Liao C, Park J-E, Bang JK, Nicklaus MC, Lee KS. Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Med Chem Lett. 2010;1(3):110-4.
43. Heckmann D, Kessler H. Design and chemical synthesis of integrin ligands. Methods Enzymol. 2007;426:463-503.
44. Heckmann D, Meyer A, Laufer B, Zahn G, Stragies R, Kessler H. Rational design of highly active and selective ligands for α5β1 integrin receptor. Chem Bio Chem. 2008;9:1397-407.
45. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol. 2008;15:459-66.
46. Watanabe N, Sekine T, Takagi M, et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem. 2009;284(4):2344-53.
47. Wishart DS, Knox C, Guo AC, et al. Drug bank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901-6.
48. http://www.organic-chemistry.org/prog/peo/. Accessed September 1, 2011.
49. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem. 2000;43:3714-7.
50. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615-23.
51. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev. 1997;23:4-25.
52. Dietzmann K, Kirches E, von Bossanyi P, Jachau K, Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol. 2001;53: 1-11.
53. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001;164:41-9.
54. http://www.rcsb.org/pdb/home/home.do. Accessed September 1, 2011.
55. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb viewer: an environment for comparative protein modeling. Electrophoresis 1997;18:2714-23. http://www.expasy.org/spdbv/. Accessed September 1, 2011.
56. Mark A. Argus Lab 4.0.1, Thompson, Planaria Software LLC, Seattle, WA, http://www.arguslab.com/. Accessed September 1, 2011.
57. http://www.molinspiration.com/. Accessed September 1, 2011.
58. Richardson CM, Williamson DS, Parratt MJ, et al. Triazolo [1,5-a] pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006;16(5):1353-7.
59. Cheng K-Y, Lowe ED, Sinclair J, Nigg EA, Johnson LN. The crystal structure of the human polo-like kinase-1 polo box domain and its phosphopeptide complex. The EMBO Journal. 2003;22:5757-68.
60. Li Z, Lazaridis T. The Effect of water displacement on binding thermodynamics: Concanavalin A. J Phys Chem B. 2005;109:662-70.